{"name":"Lyell Immunopharma","slug":"lyell","ticker":"LYEL","exchange":"NASDAQ","domain":"lyell.com","description":"Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorec","hq":"South San Francisco, CA","founded":0,"employees":"","ceo":"Lynn Seely, M.D.","sector":"Cell Therapy / Immuno-Oncology","stockPrice":22.66,"stockChange":0.88,"stockChangePercent":4.04,"marketCap":"$529M","metrics":{"revenue":36000,"revenueGrowth":-45.5,"grossMargin":100,"rdSpend":182945000,"netIncome":-274448000,"cash":247220000,"dividendYield":0,"peRatio":-27,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"rondecabtagene autoleucel","genericName":"rondecabtagene autoleucel","slug":"rondecabtagene-autoleucel","indication":"Metastatic pancreatic cancer (Phase 3)","status":"phase_3"}]}],"pipeline":[{"name":"rondecabtagene autoleucel","genericName":"rondecabtagene autoleucel","slug":"rondecabtagene-autoleucel","phase":"phase_3","mechanism":"Rondecabtagene autoleucel is a CAR-T cell therapy that genetically modifies a patient's own T cells to express a chimeric antigen receptor targeting a tumor-associated antigen, enabling the engineered cells to recognize and kill cancer cells.","indications":["Metastatic pancreatic cancer (Phase 3)","Ovarian cancer (Phase 3)"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Lyell Immunopharma Announces FDA Clearance of IND for LYEL-001","summary":"Lyell Immunopharma announced that the FDA has cleared the Investigational New Drug (IND) application for LYEL-001, a novel cell therapy for the treatment of non-Hodgkin lymphoma.","drugName":"LYEL-001","sentiment":"positive"},{"date":"2023-11-15","type":"earnings","headline":"Lyell Immunopharma Reports Third Quarter 2023 Financial Results","summary":"Lyell Immunopharma reported its third-quarter 2023 financial results, highlighting progress in its pipeline and partnerships.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPTG1pRDU5Nm9lY3pYbHczeXkzVlhhbXhFeTdPQm1tMENoMnY2U2NFazZWX2pRcDBEbjdwbXZBamNRdUwtbjFfWTUzQU96NFRXV1poTUQwYVFZOWVQOHJjWW9RdDA0XzU2T0w4UC14Z3ROWVFZaXNfQmR2UW9JZU45UnQ2MEdfTzVGRnJ6SEszMmtsN1ZYcjg3V0JQWkEtNmpUdmduUkF4aGZfTnAzSWlYZ3BtTmx0T05wc3BoRA?oc=5","date":"2026-04-07","type":"pipeline","source":"Stock Titan","summary":"Cancer drug developer Lyell will webcast a management presentation Apr. 14 - Stock Titan","headline":"Cancer drug developer Lyell will webcast a management presentation Apr. 14","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPMmloZWUxRW90bWVnM1RyUFJvSzVFOGl4UUJUTndQS0daRndmR1pWOU9iMGlZaVk0Z05QaW9USjE2Q1RaYzFXTXNlX3hQdjRfTElUWGtrVUc0cjRLOC0zS1RxNjd6UzBZUnVPbXdCdXRyT2tkWi1aeFlTVFpIMFZFZlEwUjM2WHhhazJrSXk1amtRbnBvLTFsb3FuYV9tdDVXdDRaSnFtUUtubVRkLURnTWpwZURlSC1a?oc=5","date":"2026-04-03","type":"pipeline","source":"Stock Titan","summary":"Lyell Immunopharma registers 1.95M shares for resale (NASDAQ: LYEL) - Stock Titan","headline":"Lyell Immunopharma registers 1.95M shares for resale (NASDAQ: LYEL)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPNjNvMWV0cEo4QzRXdTVpVnp0YnFrMDFJUEh1TU16Nms2aVBxc0FVWEVPTTR0cWlSamRlQy1QT3E4X05YZ1NxbUx4M3dNbEhCNFA2NmxyckFhbE5NdDlsRl9aT1ltU3NzS2k2Nlp5el9CeWpIb0tSWjhWcV9ral9ueDFLYU0xMFhUN1hTa0E4Y2lOUk5sNlNhaDV0dGwzTENiQzhaMF82OEEtMThaUVE?oc=5","date":"2026-04-01","type":"deal","source":"MarketBeat","summary":"Lyell Immunopharma (NASDAQ:LYEL) Trading Up 9.2% - Time to Buy? - MarketBeat","headline":"Lyell Immunopharma (NASDAQ:LYEL) Trading Up 9.2% - Time to Buy?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOcjJuZHVSMTlwZXlYZjYtY01VZlpwV1VyaFAyNW5wTzdCbEZaRDVabU1uVVJ4SjdUN1RsYXlvdW9fMm1LMTJ2QzV4TzdObU85SUNNLUt1N0FtTmRuekRaUmdRaWg0WXhRVFBXUG5pYkZXTndyX1JXNTlLYnpXMk1raGRnODFVbHh3dlk1QVJUWldUeVRreVBtb0ItQUU4YS1lNUkzaUhBX0VuT180TGxfOTN1YzZVdnE4VkVPT3FSNXhnRGM?oc=5","date":"2026-03-28","type":"pipeline","source":"MarketBeat","summary":"Lyell Immunopharma (NASDAQ:LYEL) Lowered to Sell Rating by Wall Street Zen - MarketBeat","headline":"Lyell Immunopharma (NASDAQ:LYEL) Lowered to Sell Rating by Wall Street Zen","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPUVRpR2xBLTk5X0xRUl9hSzhCZ3RCaS0zV0xYX0ttWnRaZGxtMlJ1NkZzUWdJVERJRG1fd1RNYnRPQWt1ek5hMktFc2Z3U1FncTVmOGlnM2VYZy1DdWZ2UGdjV00xeVVKOXQyQUJEQ0dOYUg2c2dwR0FZdnRDRUI3Rm41bHZrcXhKS0poQWRSYXFpb1FZQkV0bk1BbWRzVUFIR05SeVdKSEJEQjhYNnZBVw?oc=5","date":"2026-03-23","type":"trial","source":"Seeking Alpha","summary":"Lyell Immunopharma: Strong Early CAR-T Data, And Now A More Measured Bet (NASDAQ:LYEL) - Seeking Alpha","headline":"Lyell Immunopharma: Strong Early CAR-T Data, And Now A More Measured Bet (NASDAQ:LYEL)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxNNG0ybFd2dUM3YU12M196VlEzc1BUV1gtWG1SREJ4dnBXd0Q5cUtNMUVjQUYxUTQta2lWTWtZUE9CSU1sVDRzeUFwNkQzTkllU0ZWRWs4TkpPVnZJOW84d1ZCRXNnTWdveHVGeXpNbzVQU3o0ZjF4U0Z3ODVLZUtQemZibUl4S0hhcmJQcTJSR2l3OWZtYUV6ZzZfeElFZ3AyZ2xESFdHUXRSS3BPaU1Rci1oLVY5YUFTOEk1MkJxcW1UQ05fakpiSkJPdHJ3WmQ5ZmVyMHVJejA?oc=5","date":"2026-03-16","type":"deal","source":"MarketBeat","summary":"Lyell Immunopharma, Inc. $LYEL Shares Acquired by Foresite Capital Management V LLC - MarketBeat","headline":"Lyell Immunopharma, Inc. $LYEL Shares Acquired by Foresite Capital Management V LLC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxOWGxidGtxajJIMDc5alNFd2hDczF6QlpySWZYdnNqaTdyNEN3aWtNUzVPUE9LZ0FFQ09zZFp5ZFd2SEZxdHc5cjJrZ2ozSVM2Mkg0dUhNQng3VlBJZllCOUZYWXFDLXJNSTNoSVlzX05KQm9vOXFCaGZkcERTLWZLMGd6SzVXbnJ1Z2FuX1Q1N0VwVmJfYjFEeEV5Xy1yREhhSFlUXzlld3NKUzcyZl93d1lMUFZLOFhjNWdXNzVTZENncnZVeUJmSTdDTUVnRHphdm56ZHdYRUYzeGRnNjZoQzNRSTM3dw?oc=5","date":"2026-03-12","type":"earnings","source":"globenewswire.com","summary":"Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results - globenewswire.com","headline":"Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results","sentiment":"neutral"},{"date":"2026-03-12","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQTXFXUWJ3bUFzY0t4ODdUMm9XTFFDRXlmV0hMZ0hheHl5ZTBIbmJVN054SHJQQ1c2OFFraVZyRjdLSkFrNHd5UzExb2gxNGpjY2Q1aXI0SXhpMVRqYzNpa2V6QldWVXpfclJRR05LSFRhc2dCYnVwYlVvOTNhY3FHYXh3Rm56TDhQS3pLVVN6Nm9sN0QwY2J6aVk3Qm94ZDZpTzNrMUFCLUFQT0d2YjcxMGJHTTZmbk0?oc=5","date":"2026-03-09","type":"pipeline","source":"Stock Titan","summary":"Cancer cell therapy milestone brings Lyell $50M cash boost and new CFO - Stock Titan","headline":"Cancer cell therapy milestone brings Lyell $50M cash boost and new CFO","sentiment":"neutral"},{"date":"2026-03-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wJBVV95cUxPYmktM0FDUTdBYUhjUHk3Z3ZYWm9VeDBGdEhkbnV5Skc0dVpVaTJWZXIzczI3ZkZ2N1dKQ25fdlFoMlFWdjRkekk3MnBQczRHVlNlUDhPcHVfV0RNdUJpU09FMWVYZ2YtZWF0X0tESGNQZlloX0hIYXBoekdUcC03cjQtNVUtSFVUYmh6Q2ZuUmJZczJsOElJZEJqdFYxZnFPOWJOLTFiRFNEZXU4N0x3dWdxaHV3Rkhsd1hjNFdqcGJGdElyalc2cW8teUtfNVJnZlNWaDMtZl9VeTd4cl9yeW80bEVnYzdTZlB6ZTVxcTBfMkpXdTRYSDBDWmwzeVhiN29vZEpESWsxeW55WHFkMHMxQVFwblFPdUZhUWdRRnFuZTJDQnJtMjlFQkxCT09majd6eEQ5OFA5MnZFZXV1WXZVM1lQZnNGOXZiRkxFRVFrMVU?oc=5","date":"2026-02-12","type":"trial","source":"globenewswire.com","summary":"Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma - globenewswire.com","headline":"Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPNkU1elhvRnFzOHByWDdUNXdGLW1tNGVkejVJOGd4RjNzd1RLalN1ZFBGa2xwMS04U3Q5cm5ITEVGSS12VlRZYXA5QXAyNWNfdjNMS0JNLWY3ajNqYlpEbDRpRW5rVVhOVjEyR185VEI5WnVBWGhGTlpLVktxc3JiSTdJVm5VVWx6b3hnTWhtSi00dHJpZThTcVpEdXhjWFI4MFBXV1Bn?oc=5","date":"2025-12-24","type":"trial","source":"Seeking Alpha","summary":"Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data (NASDAQ:LYEL) - Seeking Alpha","headline":"Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data (NASDAQ:LYEL)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQb1ZVZklLU25DUVRsVHdVZFJ0aUFPNzd5NzlsNGkwc0NNVzVwRVNQYWNHeVc2UzZKdVBuWlFvRmw3bng1ZGp3aEZieDlyWnZYRHBhSWNYOWZyUElLYTFhZURPRlNpbllOdXR2eUU0VEh5VGZNZksxcnd3MjB6dGdsN3Rvemw3eUgwSDdZR3hFdGR1UVpfalRz?oc=5","date":"2025-12-17","type":"pipeline","source":"Yahoo Finance","summary":"Institutional investors are Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) biggest bettors and were rewarded after last week's US$72m market cap gain - Yahoo Finance","headline":"Institutional investors are Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) biggest bettors and were rewarded after last week's","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-22","type":"pipeline","source":"simplywall.st","summary":"Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) one-year returns climbed after last week's 13% gain, institutional investors must be happy - simplywall.st","headline":"Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) one-year returns climbed after last week's 13% gain, institutional investors mu","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Gilead Sciences","Novartis"],"therapeuticFocus":["Oncology","Immunotherapy"],"financials":{"source":"sec_edgar+yahoo","revenue":36000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":36000,"period":"2025-12-31"},{"value":61000,"period":"2024-12-31"},{"value":61000,"period":"2024-12-31"},{"value":130000,"period":"2023-12-31"},{"value":130000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":182945000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-274448000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":340052000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":0,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":22.66,"previousClose":21.78,"fiftyTwoWeekHigh":45,"fiftyTwoWeekLow":7.65,"fiftyTwoWeekRange":"7.65 - 45.0","fiftyDayAverage":22.83,"twoHundredDayAverage":18.63,"beta":-0.07,"enterpriseValue":311403584,"forwardPE":-27,"priceToBook":1.94,"priceToSales":14683.93,"enterpriseToRevenue":8650.1,"enterpriseToEbitda":-1.67,"pegRatio":0,"ebitda":-186746000,"ebitdaMargin":0,"freeCashflow":-81467128,"operatingCashflow":-150024000,"totalDebt":50994000,"debtToEquity":20.5,"currentRatio":5.28,"returnOnAssets":-29.8,"returnOnEquity":-87,"analystRating":"","recommendationKey":"none","numberOfAnalysts":4,"targetMeanPrice":32.5,"targetHighPrice":45,"targetLowPrice":12,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":25.2,"institutionHeldPercent":53.7,"sharesOutstanding":23328390,"floatShares":13908305,"sharesShort":940269,"shortRatio":9.48,"shortPercentOfFloat":4,"epsTrailing":-16.06,"epsForward":-0.84,"revenuePerShare":0,"bookValue":11.68,"officers":[{"age":73,"name":"Dr. Richard D. Klausner M.D.","title":"Founder & Executive Chairman"},{"age":66,"name":"Dr. Lynn  Seely M.D., Ph.D.","title":"Principal Executive Officer, President, CEO & Director"},{"age":54,"name":"Mr. Stephen J. Hill","title":"Chief Operating Officer"},{"age":null,"name":"Prof. Stanley R. Riddell M.D.","title":"Founder & Scientific Advisor"},{"age":64,"name":"Dr. Crystal L. Mackall M.D.","title":"Founder & Scientific Advisor"},{"age":49,"name":"Ms. Smital  Shah M.B.A.","title":"Principal Financial Officer, CFO & Chief Business Officer"},{"age":null,"name":"Nellie  Dillery","title":"Director of Accounting"},{"age":47,"name":"Dr. Gary K. Lee Ph.D.","title":"Chief Scientific Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.lyell.com","phone":"650 695 0677"}}